Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2024; 16(6): 900-911
Published online Jun 27, 2024. doi: 10.4254/wjh.v16.i6.900
Hepatitis B cure: Current situation and prospects
Ya-Ping Li, Chen-Rui Liu, Ling He, Shuang-Suo Dang
Ya-Ping Li, Chen-Rui Liu, Ling He, Shuang-Suo Dang, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Co-first authors: Ya-Ping Li and Chen-Rui Liu.
Author contributions: Li YP and Liu CR contributed equally to this work; Li YP, Liu CR, and Dang SS collaboratively contributed to the completion of this manuscript; He L is responsible for collecting, summarizing, and organizing reference materials. Dang SS was responsible for the conceptual design of the article; Li YP and Liu CR made equal contribution to this article.
Supported by National Key Research and Development Program of China 2023, No: 2023YFC2308100.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shuang-Suo Dang, PhD, Professor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 Xiwu Road, Xi’an 710004, Shaanxi Province, China. dang212@126.com
Received: March 24, 2024
Revised: May 5, 2024
Accepted: June 3, 2024
Published online: June 27, 2024
Processing time: 87 Days and 22.2 Hours
Core Tip

Core Tip: Clinical cure has become an ideal goal pursued by chronic hepatitis B (CHB) patients. To enable more patients to achieve this goal, immunotherapy targets, the development of drugs targeting the viral life cycle, gene editing technologies, and the application of other methods have promoted the achievement of a clinical cure for CHB; however, this topic warrants continuous exploration.